Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder
Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder
Objective: trichotillomania and skin-picking disorder are underrecognized and often disabling conditions in which individuals repeatedly pull at their hair or pick at their skin, leading to noticeable hair loss or tissue damage. To date there is a severe paucity of evidence-based treatments for these conditions. In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing hair-pulling and skin-picking behavior.
Methods: one hundred adults with trichotillomania or skin-picking disorder (86 women; mean age, 31.4 years [SD=10.2]) were enrolled in a double-blind trial of memantine (dosing range, 10-20 mg/day) or placebo for 8 weeks. Participants were assessed with measures of pulling and picking severity. Outcomes were examined using a linear mixed-effects model. The prespecified primary outcome measure was treatment-related change on the NIMH Trichotillomania Symptom Severity Scale, modified to include skin picking.
Results: compared with placebo, memantine treatment was associated with significant improvements in scores on the NIMH scale, Sheehan Disability Scale, and Clinical Global Impressions severity scale in terms of treatment-by-time interactions. At study endpoint, 60.5% of participants in the memantine group were "much or very much improved," compared with 8.3% in the placebo group (number needed to treat=1.9). Adverse events did not differ significantly between the treatment arms.
Conclusions: this study found that memantine treatment resulted in statistically significant reductions in hair pulling and skin-picking symptoms compared with placebo, with relatively high efficacy (based on number needed to treat), and was well tolerated. The glutamate system may prove to be a beneficial target in the treatment of compulsive behaviors.
Obsessive-Compulsive Disorder (OCD), Pharmacotherapy, Psychopharmacology
348-356
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Chesivoir, Eve
4dbc225b-0ae3-425c-baae-a4cd3b62b4bc
Valle, Stephanie
fdb6f4ca-a7e1-4e3d-bbf5-4dd380570aa5
Ehsan, Dustin
ecfc1fc9-0b73-4686-bff3-f3c15d8c7a17
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
1 May 2023
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Chesivoir, Eve
4dbc225b-0ae3-425c-baae-a4cd3b62b4bc
Valle, Stephanie
fdb6f4ca-a7e1-4e3d-bbf5-4dd380570aa5
Ehsan, Dustin
ecfc1fc9-0b73-4686-bff3-f3c15d8c7a17
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Grant, Jon E., Chesivoir, Eve, Valle, Stephanie, Ehsan, Dustin and Chamberlain, Samuel R.
(2023)
Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder.
American Journal of Psychiatry, 180 (5), .
(doi:10.1176/appi.ajp.20220737).
Abstract
Objective: trichotillomania and skin-picking disorder are underrecognized and often disabling conditions in which individuals repeatedly pull at their hair or pick at their skin, leading to noticeable hair loss or tissue damage. To date there is a severe paucity of evidence-based treatments for these conditions. In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing hair-pulling and skin-picking behavior.
Methods: one hundred adults with trichotillomania or skin-picking disorder (86 women; mean age, 31.4 years [SD=10.2]) were enrolled in a double-blind trial of memantine (dosing range, 10-20 mg/day) or placebo for 8 weeks. Participants were assessed with measures of pulling and picking severity. Outcomes were examined using a linear mixed-effects model. The prespecified primary outcome measure was treatment-related change on the NIMH Trichotillomania Symptom Severity Scale, modified to include skin picking.
Results: compared with placebo, memantine treatment was associated with significant improvements in scores on the NIMH scale, Sheehan Disability Scale, and Clinical Global Impressions severity scale in terms of treatment-by-time interactions. At study endpoint, 60.5% of participants in the memantine group were "much or very much improved," compared with 8.3% in the placebo group (number needed to treat=1.9). Adverse events did not differ significantly between the treatment arms.
Conclusions: this study found that memantine treatment resulted in statistically significant reductions in hair pulling and skin-picking symptoms compared with placebo, with relatively high efficacy (based on number needed to treat), and was well tolerated. The glutamate system may prove to be a beneficial target in the treatment of compulsive behaviors.
This record has no associated files available for download.
More information
Accepted/In Press date: 12 January 2023
e-pub ahead of print date: 22 February 2023
Published date: 1 May 2023
Keywords:
Obsessive-Compulsive Disorder (OCD), Pharmacotherapy, Psychopharmacology
Identifiers
Local EPrints ID: 492736
URI: http://eprints.soton.ac.uk/id/eprint/492736
ISSN: 1535-7228
PURE UUID: 030dbe88-bdf1-4379-8c53-68d4207fc351
Catalogue record
Date deposited: 13 Aug 2024 16:38
Last modified: 13 Nov 2024 03:00
Export record
Altmetrics
Contributors
Author:
Jon E. Grant
Author:
Eve Chesivoir
Author:
Stephanie Valle
Author:
Dustin Ehsan
Author:
Samuel R. Chamberlain
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics